Clinical Scorecard: Editorial: An In-Depth Exploration of Brugada Syndrome Through Time: Historical Insights and Future Directions

At a Glance

Key Highlights

• Brugada syndrome is defined by its electrocardiographic phenotype and underlying arrhythmogenic substrate.
• Advances in high-density mapping have identified abnormal electrograms linked to ventricular arrhythmias.
• Epicardial substrate ablation has shown success in symptomatic patients, normalizing ECG patterns.
• Risk stratification models are evolving but remain inconsistent in predictive performance.
• Genetic testing has limited specificity, with pathogenic variants found in a minority of patients.

Guideline-Based Recommendations

Diagnosis

• Refine diagnostic criteria to reduce the weight of drug-induced ECG patterns in asymptomatic patients.

Management

• Consider epicardial substrate ablation for symptomatic patients with Brugada syndrome.

Monitoring & Follow-up

• Utilize contemporary risk stratification models that integrate clinical, electrocardiographic, electrophysiological, and genetic variables.

Risks

• Inconsistent risk stratification may lead to uncertainty in management decisions.

Patient & Prescribing Data

Patients with Brugada syndrome, including both symptomatic and asymptomatic individuals.

Successful management may involve substrate ablation and careful monitoring of ECG patterns.

Clinical Best Practices

• Utilize high-density mapping for better understanding of arrhythmogenic substrates.
• Incorporate evolving risk stratification models into clinical practice.

Related Resources & Content

• Brugada Syndrome Overview